SMT C1100: Phase Ib data

A placebo-controlled, U.K. Phase Ib trial in 12 ambulatory DMD patients ages 5-13 showed that twice-daily 2,500 mg SMT C1100 for 14 days met the primary endpoint of 50% of patients achieving desired p...